Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Sweta Killa headshot

5 Small-Cap ETFs to Profit From the January Effect

After registering double-digit annual growth, Wall Street is poised to gain from the historical trend of January Effect.

Best Growth Stocks to Buy for January 5th

ABG, APO, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 5, 2022

AbbVie (ABBV) Gets FDA Breakthrough Tag for Lung Cancer Drug

AbbVie's (ABBV) Breakthrough Therapy Designation for Teliso-V is based on data from the phase II LUMINOSITY study.

Should Principal U.S. MegaCap ETF (USMC) Be on Your Investing Radar?

Style Box ETF report for USMC

The Zacks Analyst Blog Highlights: Meta Platforms, Inc., Bank of America Corporation, Mastercard Inc., Pfizer Inc. and Medtronic plc

Meta Platforms, Inc., Bank of America Corporation and Mastercard Inc., Pfizer Inc. and Medtronic plc are highlighted in this analyst blog.

Sheraz Mian headshot

Top Stock Reports for Meta Platforms, Bank of America & Mastercard

Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (FB), Bank of America Corporation (BAC), and Mastercard Incorporated (MA).

Here's Why Momentum Investors Will Love Pfizer (PFE)

Does Pfizer (PFE) have what it takes to be a top stock pick for momentum investors? Let's find out.

PFE vs. RHHBY: Which Stock Should Value Investors Buy Now?

PFE vs. RHHBY: Which Stock Is the Better Value Option?

Pfizer, BioNTech Booster Gets FDA Nod for 12 to 15-Year Olds

FDA authorizes the booster shot of Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine for adolescents 12 through 15 years of age.

New Strong Buy Stocks for January 4th

ABG, CNTY, IIJIY, ORAN, and PFE have been added to the Zacks Rank #1 (Strong Buy) List on January 4, 2022.

Spero (SPRO) Application for UTI Drug Gets Priority Review

Spero's (SPRO) NDA for tebipenem HBr oral tablets for complicated urinary tract infections gets Priority Review.

Best Growth Stocks to Buy for January 4th

ABG, PFE, and APO made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 4, 2022

Company News for Jan 3, 2022

Companies In The News Are: PFE, CTRA, AMD, XLNX, NVAX.

Novavax (NVAX) Further Delays FDA Filing for COVID-19 Vaccine

Novavax's (NVAX) filing with the FDA seeking approval for emergency use authorization of its COVID-19 vaccine, NVX-CoV2373, gets further postponed to January 2022.

Kinjel Shah headshot

Here's Why Pfizer (PFE) Appears Strongly Placed for 2022

While the COVID vaccine should continue to boost Pfizer (PFE) revenues in 2022, Paxlovid is also likely to become an important top-line driver

J&J (JNJ) COVID Booster Jab Shows Effectiveness Against Omicron

Johnson & Johnson's (JNJ) COVID booster vaccine demonstrates 85% effectiveness against COVID-related hospitalization in South Africa, with Omicron becoming the dominant variant.

Ocugen (OCGN) Up on Bharat Biotech's Data in Pediatric Group

Ocugen (OCGN) gains on Bharat Biotech's positive results from a study in the pediatric population.

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

Pfizer (PFE) closed the most recent trading day at $57.58, moving -0.74% from the previous trading session.

Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?

Style Box ETF report for SCHD

Sweta Killa headshot

5 Sector ETFs That Crushed the Market in December

With just a few trading sessions left to end December, the S&P 500 index has gained 4.8%. A few sector ETFs have outperformed.

Novavax (NVAX) COVID Jab Gets Nod for Emergency Use in India

Novavax (NVAX) secures approval in India for emergency use of its COVID-19 vaccine.

Can Veklury Sales Retain Momemtum for Gilead (GILD) in 2022?

Solid sales from Veklury cushion Gilead (GILD) in 2021 amid COVID-19. However, new oral antivirals in the market might hurt sales. GILD now shifts focus to oncology as the virology space faces issues.

Sweta Killa headshot

Holiday Sales Boom: Retail ETFs to Buy At a Bargain

Retail sales surged the most in nearly two decades this holiday season powered by soaring ecommerce sales as well as a rush to stores amid supply chain concerns, rising inflation and the raging new COVID-19 variant.

Stock Market News for Dec 27, 2021

U.S. stocks closed higher for the third consecutive day on Thursday, with the S&P 500 hitting a record high ahead of a long Christmas holiday weekend as investors shed fears and felt more optimistic that the Omicron variant of the coronavirus won¿¿¿t affect global economy growth.

Merck's (MRK) COVID Pill Gets FDA Nod for Emergency Use

Merck's (MRK) oral antiviral molnupiravir secures the FDA-authorized emergency use tag in treating mild-to-moderate COVID-19 in adults for whom other FDA-approved COVID treatments are unsuitable.